$2.00
-0.12 (-5.66%)
Open$2.09
Previous Close$2.12
Day High$2.15
Day Low$1.98
52W High$28.67
52W Low$10.08
Volume—
Avg Volume419.0K
Market Cap213.94M
P/E Ratio28.22
EPS$0.71
SectorBiotechnology
Analyst Ratings
Sell
13 analysts
Price Target
+965.0% upside
Current
$2.00
$2.00
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.95M | 87.33M | 87.17M |
| Net Income | 6.08M | 8.20M | 6.12M |
| Profit Margin | 6.7% | 9.4% | 7.0% |
| EBITDA | 10.53M | 10.19M | 12.10M |
| Free Cash Flow | 5.16M | 6.96M | 5.08M |
| Rev Growth | -3.1% | +6.5% | -4.4% |
| Debt/Equity | 0.48 | 0.50 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |